Johnson & Johnson filed a Form 8-K with the SEC on August 4, 2026, disclosing that a senior executive will retire from her role effective September 1, 2026.

Key Highlights

  • Retiring executive: Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee.
  • Effective date: The retirement is effective September 1, 2026.
  • Announcement date: The company announced the retirement on August 4, 2026.
  • Supporting document: A press release dated August 4, 2026 is attached to the filing as Exhibit 99.1.

Jennifer Taubert to Step Down from Johnson & Johnson Leadership Role

According to the Form 8-K filed by Johnson & Johnson (NYSE: JNJ) on August 4, 2026, the company disclosed under Item 5.02 that Jennifer Taubert will retire from her role as Executive Vice President, Worldwide Chairman, Innovative Medicine, and member of the Executive Committee. The retirement is stated to be effective September 1, 2026.

The filing, signed by Corporate Secretary Marc Larkins, includes a press release dated August 4, 2026 as Exhibit 99.1. The company is incorporated in New Jersey and is headquartered at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. Its common stock, par value $1.00, trades on the New York Stock Exchange under the symbol JNJ, alongside several series of listed notes with maturities ranging from 2028 through 2055.

What Was Disclosed

Johnson & Johnson reported the planned retirement of Executive Vice President and Worldwide Chairman, Innovative Medicine, Jennifer Taubert, effective September 1, 2026, via an 8-K filed on August 4, 2026. A related press release was included as an exhibit.